SpringerLink
Log in

Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

References

  1. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011;118:6247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lv M, Shen M, Mo X. Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world. Innovation. 2023;4:100373.

    PubMed  PubMed Central  Google Scholar 

  3. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

    Article  PubMed  Google Scholar 

  4. Ahuja HGHJ, Aplan PD, Tcheurekdjian L, Forman SJ, Slovak ML. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res. 2000;15:6227–9.

    Google Scholar 

  5. Tosic N, Stojiljkovic M, Colovic N, Colovic M, Pavlovic S. Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review. Cancer Genet Cytogenet. 2009;193:98–103.

    Article  CAS  PubMed  Google Scholar 

  6. Wei S, Wang S, Qiu S, Qi J, Mi Y, Lin D, et al. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation. Leuk Res. 2013;37:1010–5.

    Article  CAS  PubMed  Google Scholar 

  7. Shen Y, Zhang T, Zhang L, Zhen S, Chen Z, Zhang R, et al. Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia. Bone Marrow Transplant. 2023. https://doi.org/10.1038/s41409-023-02030-3.

  8. Liu J, Ma R, Liu YR, Xu LP, Zhang XH, Chen H, et al. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant. 2019;54:567–77.

    Article  PubMed  Google Scholar 

  9. Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014;124:2400–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Michmerhuizen NLKJ, Mullighan CG. mechanistic insights and potential therapeutic targets for nup98-rearranged hematologic malignancies. Blood. 2020;136:2275–89.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mitani Y, Hiwatari M, Seki M, Hangai M, Takita J. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions. Int J Hematol. 2019;110:512–6.

    Article  PubMed  Google Scholar 

  12. Cao Y, Zhang C, Cao L, Mo X, Hu X. Quizartinib is a good option for AML patients with FLT3-ITD mutations. Innov Med. 2023;1:100007.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by National High Level Hospital Clinical Research Funding (BJ-2022-169), the National Key Research and Development Program of China (2022YFC2502600, 2022YFC2502606, 2021YFA1101503), the National Natural Science Foundation of China (82170206, 82170208), CAMS Innovation Fund for Medical Sciences (2019-I2M-5-034, 2022-I2M-C&T-B-121), Peking University People’s Hospital Research and Development Funds (RZ2022-02) and Shanghai Municipal Health Commission Project of Disciplines of Excellence (20234Z0002).

Author information

Author notes

  1. These authors contributed equally: Yang Cao, Chunli Zhang, **aosu Zhao.

Authors and Affiliations

  1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China

    Yang Cao

  2. Department of Hematology, Bei**g Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Bei**g, 100730, China

    Chunli Zhang

  3. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Bei**g Key Laboratory of Hematopoietic Stem Cell Transplantation, Bei**g, 100044, China

    **aosu Zhao & **aodong Mo

  4. Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Bei**g, 100044, China

    **aosu Zhao & **aodong Mo

  5. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui ** Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Jiayu Huang, Zilu Zhang, Chuanhe Jiang & **aoxia Hu

  6. Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Jiayu Huang, Zilu Zhang, Chuanhe Jiang & **aoxia Hu

Authors
  1. Yang Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunli Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. **aosu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiayu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zilu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chuanhe Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. **aodong Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. **aoxia Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XH and XM were responsible for the study design. YC, XZ, CZ, JH, ZZ, CJ collected the clinical data. XH, XM and YC analyzed the data and wrote the manuscript. XH and XM interpreted the results and provided feedback. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to **aodong Mo or **aoxia Hu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, Y., Zhang, C., Zhao, X. et al. Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China. Bone Marrow Transplant 58, 1413–1415 (2023). https://doi.org/10.1038/s41409-023-02106-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02106-0

  • Springer Nature Limited

Search

Navigation